Ginsenoside Rb1 for overcoming cisplatin-insensitivity of A549/DDP cells in vitro and vivo through the dual-inhibition on two efflux pumps of ABCB1 and PTCH1

Niu, Xueni; Shi, Yinuo; Li, Qiao; Chen, Hong; Fan, Xiaoyu; Yu, Yang; Lv, Chongning; Lu, Jincai

doi:10.1016/j.phymed.2023.154776

Cited by 8 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown that in NSCLC, GRb1 can decrease the expression levels of ABCB1, SHH, PTCH1, GLI2, and the apoptosis-resistant protein Bcl-2 and upregulate the expression of the cellular pro-apoptotic protein Bax, which advances the pro-apoptotic process of cisplatin. GRb1 increased the intracellular drug concentration of cisplatin by targeting ABCB1 and the Hedgehog pathway, reversing cisplatin resistance in A549/DDP cells and improving its efficacy ( 15 ). In nasopharyngeal carcinoma cells, Li et al.…”

Section: Chinese Herb Monomermentioning

confidence: 99%

Integrating Chinese medicine into mainstream cancer therapies: a promising future

Ni,

Xue,

Wang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Malignant tumors are complex systemic chronic diseases and one of the major causes of human mortality. Targeted therapy, chemotherapy, immunotherapy, and radiotherapy are examples of mainstream allopathic medicine treatments that effective for intermediate and advanced malignant tumors. The ongoing use of conventional allopathic medicine has resulted in adverse responses and drug resistance, which have hampered its efficacy. As an important component of complementary and alternative medicine, Chinese medicine has been found to have antitumor effects and has played an important role in enhancing the therapeutic sensitivity of mainstream allopathic medicine, reducing the incidence of adverse events and improving immune-related functions. The combined application of adjuvant Chinese medicine and mainstream allopathic medicine has begun to gain acceptance and is gradually used in the field of antitumor therapy. Traditional natural medicines and their active ingredients, as well as Chinese patent medicines, have been proven to have excellent therapeutic efficacy and good safety in the treatment of various malignant tumors. This paper focuses on the mechanism of action and research progress of combining the above drugs with mainstream allopathic medicine to increase therapeutic sensitivity, alleviate drug resistance, reduce adverse reactions, and improve the body’s immune function. To encourage the clinical development and use of Chinese herb adjuvant therapy as well as to provide ideas and information for creating safer and more effective anticancer medication combinations, the significant functions of Chinese herb therapies as adjuvant therapies for cancer treatment are described in detail.

show abstract

Section: Chinese Herb Monomermentioning

confidence: 99%

Integrating Chinese medicine into mainstream cancer therapies: a promising future

Ni,

Xue,

Wang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…There are a number of types and complex structures of saponins ( 136 ). Numerous saponins, including Paris saponin VII ( 137 ), ginsenoside Rb1 ( 138 ) and sodium aescinate ( 139 ), have been reported to inhibit the expression of P-gp and reverse tumor resistance. Astragaloside II has been found to increase the intracellular accumulation of P-gp substrates by inhibiting the efflux pump activity of P-gp.…”

Section: Reversing Mdr By Inhibiting P-gp Expressionmentioning

confidence: 99%

Mechanism of multidrug resistance to chemotherapy mediated by P‑glycoprotein (Review)

Tian,

Lei,

Wang

et al. 2023

Int J Oncol

View full text Add to dashboard Cite

Multidrug resistance (MDR) seriously limits the clinical application of chemotherapy. A mechanism underlying MDR is the overexpression of efflux transporters associated with chemotherapeutic drugs. P-glycoprotein (P-gp) is an ATP-binding cassette (ABC) transporter, which promotes MDR by pumping out chemotherapeutic drugs and reducing their intracellular concentration. To date, overexpression of P-gp has been detected in various types of chemoresistant cancer and inhibiting P-gp-related MDR has been suggested. The present review summarizes the mechanisms underlying MDR mediated by P-gp in different tumors and evaluated the related signaling pathways, with the aim of improving understanding of the current status of P-gp-mediated chemotherapeutic resistance. This review focuses on the main mechanisms of inhibiting P-gp-mediated MDR, with the aim of providing a reference for the study of reversing P-gp-mediated MDR. The first mechanism involves decreasing the efflux activity of P-gp by altering its conformation or hindering P-gp-chemotherapeutic drug binding. The second inhibitory mechanism involves inhibiting P-gp expression to reduce efflux. The third inhibitory mechanism involves knocking out the ABCB1 gene. Potential strategies that can inhibit P-gp include certain natural products, synthetic compounds and biological techniques. It is important to screen lead compounds or candidate techniques for P-gp inhibition, and to identify inhibitors by targeting the relevant signaling pathways to overcome P-gp-mediated MDR.

show abstract

“…ABCB1, also known as multidrug resistance protein 1 (MDR1) or Pglycoprotein, is an important member of the ABC family and confers drug resistance in cancer cells [17,18]. In recent years, numerous traditional Chinese medicines (TCMs) have been identified as effective in reversing chemotherapy resistance by affecting ABCB1 expression [19][20][21]. Due to their low toxicity, minor side effects, and ability to target multiple pathways, TCMs have received increasing attention for their potential application in the treatment of cancer drug resistance.…”

Section: Introductionmentioning

confidence: 99%

Targeted inhibition of the HNF1A/SHH axis by triptolide overcomes paclitaxel resistance in non-small cell lung cancer

Li,

Yang,

Liu

et al. 2024

Acta Pharmacol Sin

View full text Add to dashboard Cite

Paclitaxel resistance is associated with a poor prognosis in non-small cell lung cancer (NSCLC) patients, and currently, there is no promising drug for paclitaxel resistance. In this study, we investigated the molecular mechanisms underlying the chemoresistance in human NSCLC-derived cell lines. We constructed paclitaxel-resistant NSCLC cell lines (A549/PR and H460/PR) by long-term exposure to paclitaxel. We found that triptolide, a diterpenoid epoxide isolated from the Chinese medicinal herb Tripterygium wilfordii Hook F, effectively enhanced the sensitivity of paclitaxel-resistant cells to paclitaxel by reducing ABCB1 expression in vivo and in vitro. Through high-throughput sequencing, we identified the SHH-initiated Hedgehog signaling pathway playing an important role in this process. We demonstrated that triptolide directly bound to HNF1A, one of the transcription factors of SHH, and inhibited HNF1A/SHH expression, ensuing in attenuation of Hedgehog signaling. In NSCLC tumor tissue microarrays and cancer network databases, we found a positive correlation between HNF1A and SHH expression. Our results illuminate a novel molecular mechanism through which triptolide targets and inhibits HNF1A, thereby impeding the activation of the Hedgehog signaling pathway and reducing the expression of ABCB1. This study suggests the potential clinical application of triptolide and provides promising prospects in targeting the HNF1A/SHH pathway as a therapeutic strategy for NSCLC patients with paclitaxel resistance.

show abstract

Ginsenoside Rb1 for overcoming cisplatin-insensitivity of A549/DDP cells in vitro and vivo through the dual-inhibition on two efflux pumps of ABCB1 and PTCH1

Cited by 8 publications

References 35 publications

Integrating Chinese medicine into mainstream cancer therapies: a promising future

Integrating Chinese medicine into mainstream cancer therapies: a promising future

Mechanism of multidrug resistance to chemotherapy mediated by P‑glycoprotein (Review)

Targeted inhibition of the HNF1A/SHH axis by triptolide overcomes paclitaxel resistance in non-small cell lung cancer

Contact Info

Product

Resources

About